Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide

J. R. Sheu, T. F. Huang

研究成果: 雜誌貢獻文章同行評審

15 引文 斯高帕斯(Scopus)

摘要

Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.

原文英語
頁(從 - 到)58-62
頁數5
期刊Journal of Pharmacy and Pharmacology
46
發行號1
出版狀態已發佈 - 1994
對外發佈

ASJC Scopus subject areas

  • 藥理
  • 藥學科學

指紋

深入研究「Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide」主題。共同形成了獨特的指紋。

引用此